Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial
Cyclic GMP–phosphodiesterase type 5 (PDE5) inhibition has been shown to counteract
maladaptive cardiac changes triggered by diabetes in some but not all studies. We …
maladaptive cardiac changes triggered by diabetes in some but not all studies. We …
Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with …
Background—cGMP phosphodiesterase type 5 protein is upregulated in myocardial
hypertrophy. However, it has never been ascertained whether phosphodiesterase type 5 …
hypertrophy. However, it has never been ascertained whether phosphodiesterase type 5 …
Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation …
Diabetic patients are prone to metabolic perturbations that progressively contribute to
structural, functional and proteomic alterations in the myocardium. Phosphodiesterase-5 …
structural, functional and proteomic alterations in the myocardium. Phosphodiesterase-5 …
Phosphodiesterase 5 associates with β2 adrenergic receptor to modulate cardiac function in type 2 diabetic hearts
TM West, Q Wang, B Deng, Y Zhang… - Journal of the …, 2019 - Am Heart Assoc
Background In murine heart failure models and in humans with diabetic‐related heart
hypertrophy, inhibition of phosphodiesterase 5 (PDE 5) by sildenafil improves cardiac …
hypertrophy, inhibition of phosphodiesterase 5 (PDE 5) by sildenafil improves cardiac …
PDE5 inhibitor efficacy is estrogen dependent in female heart disease
H Sasaki, T Nagayama, RM Blanton… - The Journal of …, 2014 - Am Soc Clin Investig
Inhibition of cGMP-specific phosphodiesterase 5 (PDE5) ameliorates pathological cardiac
remodeling and has been gaining attention as a potential therapy for heart failure. Despite …
remodeling and has been gaining attention as a potential therapy for heart failure. Despite …
Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase‐5A inhibitor vardenafil in rats with type 2 diabetes
Aims Heart failure with preserved ejection fraction (HFpEF) has a great epidemiological
burden. The pathophysiological role of cyclic guanosine monophosphate (cGMP) signalling …
burden. The pathophysiological role of cyclic guanosine monophosphate (cGMP) signalling …
Mineralocorticoid receptor antagonist improves cardiac structure in type 2 diabetes: data from the MIRAD trial
NH Brandt-Jacobsen, P Lav Madsen, ML Johansen… - Heart Failure, 2021 - jacc.org
Objectives This study investigated the impact of the MR antagonist (MRA) eplerenone on
LVM in type 2 diabetes patients at high risk for cardiovascular disease (CVD). Background …
LVM in type 2 diabetes patients at high risk for cardiovascular disease (CVD). Background …
The phosphodiesterase‐5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus
T Radovits, T Bömicke, G Kökény, R Arif… - British journal of …, 2009 - Wiley Online Library
Background and purpose: Patients with diabetes mellitus exhibit generalized endothelial
and cardiac dysfunction with decreased nitric oxide production. Elevated intracellular cyclic …
and cardiac dysfunction with decreased nitric oxide production. Elevated intracellular cyclic …
Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality
Objective Experimental evidence has shown potential cardioprotective actions of
phosphodiesterase type-5 inhibitors (PDE5is). We investigated whether PDE5i use in …
phosphodiesterase type-5 inhibitors (PDE5is). We investigated whether PDE5i use in …
Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials
Background The myocardial effects of phosphodiesterase type 5 inhibitors (PDE5i) have
recently received consideration in several preclinical studies. The risk/benefit ratio in …
recently received consideration in several preclinical studies. The risk/benefit ratio in …